Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer [corrected] [published erratum appears in J CLIN ONCOL 2005 Jan 1;23(1):248].

PurposeChildren surviving acute lymphoblastic leukemia (ALL) and malignant brain tumors (BTs) have a higher incidence of attention and learning problems in school than do their healthy peers. The present study tests the hypothesis that the psychostimulant methylphenidate (MPH) improves cognitive and...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Clinical Oncology Vol. 22; no. 23; pp. 4743 - 4752
Autores principales: Mulhern RK, Khan RB, Kaplan S, Helton S, Christensen R, Bonner M, Brown R, Xiong X, Wu S, Gururangan S, Reddick WE
Formato: clinical trial research tables/charts Journal Article
Publicado: American Society of Clinical Oncology 12/1/2004
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106492267&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 106492267
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        0732183X
        20D
      jtl: Journal of Clinical Oncology
      issn: 0732183X
      maglogo: N
    pubinfo:
      dt: 12/1/2004
      vid: 22
      iid: 23
      pid: 26892
      pub: American Society of Clinical Oncology
      place: Alexandria, Virginia
    artinfo:
      ui:
        106492267
        106492267
        2005113833
        NLM15570081
        106492267
      ppf: 4743
      ppct: 9
      formats:
      tig:
        atl: Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer [corrected] [published erratum appears in J CLIN ONCOL 2005 Jan 1;23(1):248].
      aug:
        au:
          Mulhern RK
          Khan RB
          Kaplan S
          Helton S
          Christensen R
          Bonner M
          Brown R
          Xiong X
          Wu S
          Gururangan S
          Reddick WE
        affil: Division of Behavioral Medicine, St Jude Children's Research Hospital, 332 N Lauderdale, Memphis, TN 38105-2794; raymond.mulhern@stjude.org
      sug:
        subj:
          Cancer Survivors In Infancy and Childhood
          Methylphenidate Therapeutic Use
          Attention Deficit Hyperactivity Disorder Drug Therapy
          Cognition Disorders Drug Therapy
          Treatment Complications, Delayed
          Attention Deficit Hyperactivity Disorder Etiology
          Neuropsychological Tests
          Behavior Rating Scales
          Scales
          Checklists
          Child Behavior Checklist
          Cognition Disorders Etiology
          Leukemia, Lymphocytic, Acute Complications
          Leukemia, Lymphocytic, Acute Complications
          Brain Neoplasms Complications
          Attention Deficit Hyperactivity Disorder Physiopathology
          Cognition Disorders Physiopathology
          Brain Neoplasms Therapy
          Brain Neoplasms Therapy
          Clinical Trials
          Crossover Design
          Data Analysis Software
          Repeated Measures
          Analysis of Variance
          Child
          Adolescence
          Female
          Male
          Funding Source
          Human
          Child: 6-12 years
          Adolescent: 13-18 years
          Female
          Male
      ab: PurposeChildren surviving acute lymphoblastic leukemia (ALL) and malignant brain tumors (BTs) have a higher incidence of attention and learning problems in school than do their healthy peers. The present study tests the hypothesis that the psychostimulant methylphenidate (MPH) improves cognitive and social functioning among these patients.Patients and MethodsWe report on 83 long-term survivors of ALL and BT identified as having attentional deficits on behavioral testing and parent or teacher report, and problems with academic achievement. The 47 male and 36 female patients ranged from 0.6 to 14.3 years (median, 5.4 years) of age at diagnosis and 6.7 to 17.9 years (median, 11.9 years) of age at participation. The patients (40 ALL, 43 BT) participated in a randomized, double-blind, 3-week home cross-over trial of placebo (bid), low-dose MPH (0.3 mg/kg; maximum dose, 10 mg bid), and moderate-dose MPH (0.6 mg/kg; maximum dose, 20 mg bid). The primary end points were weekly teacher and parent reports on the Conners' Rating Scales and Social Skills Rating System.ResultsCompared to placebo, significant improvement with MPH was reported by teachers and parents on the Conners' Rating Scales and by teachers on the Social Skills Rating System. However, no consistent advantage of moderate dose over low dose was observed. Of those participating, 66 (79.5%) of the 83 patients continued on best clinical management.ConclusionTreatment with MPH can at least temporarily reduce some attentional and social deficits among survivors of childhood ALL and BT. Long-term follow-up will reveal those subsets of patients who are more likely to benefit from MPH.
      pubtype: Academic Journal
      doctype:
        clinical trial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N